The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.